Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CA81732W1041
Wed, 22.03.2023
Sernova Corp.
Sernova Announces Abstract on First Cohort of its Phase 1/2 Study Involving Islet Allotransplantation into Pre-vascularized Cell PouchTM Selected for Oral Podium Presentation at American Diabetes Association 83rd Scientific Sessions 2023
LONDON, Ontario – March 22, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage com [ … ]
Tue, 14.03.2023
Sernova Corp.
First pre-clinical data presentation of Sernova’s Cell Pouch with Evotec’s iPSC derived islet-like cluster technology for type 1 diabetes (T1D)
LONDON, Ontario – March 14, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that an abstract has been selected for an [ … ]
Tue, 14.03.2023
Sernova Corp.
First pre-clinical data presentation of Sernova’s Cell Pouch with Evotec’s iPSC derived islet-like cluster technology for type 1 diabetes (T1D)
LONDON, Ontario – March 14, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that an abstract has been selected for an [ … ]
Wed, 08.03.2023
Sernova Corp.
Third patient now implanted with higher capacity, 10-chamber Cell Pouch
Company anticipates first interim data from second cohort in Q4, 2023
LONDON, Ontario – March 8, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that the first two patients in the second [ … ]
Wed, 08.03.2023
Sernova Corp.
Third patient now implanted with higher capacity, 10-chamber Cell Pouch
Company anticipates first interim data from second cohort in Q4, 2023
LONDON, Ontario – March 8, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that the first two patients in the second [ … ]
Thu, 02.03.2023
Sernova Corp.
- Sernova provides warrant update
LONDON, Ontario – March 2, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be participating in the upcoming 35th Annual Roth Conference being held March 12-14, 2023 and the Oppenheimer 33rd Annual Healthcare Conference, [ … ]
Thu, 02.03.2023
Sernova Corp.
- Sernova provides warrant update
LONDON, Ontario – March 2, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be participating in the upcoming 35th Annual Roth Conference being held March 12-14, 2023 and the Oppenheimer 33rd Annual Healthcare Conference, [ … ]
Mon, 30.01.2023
Sernova Corp.
Preclinical proof of concept study demonstrates that thyroid auto-transplantation into the Cell Pouch can restore thyroid hormone production following removal of the thyroid gland
Sernova has engaged with regulatory authorities towards initiating clinical development of a prospective therapy for hypothyroidism
LONDON, Ontario – January 30, 2023 – [ … ]
Tue, 10.01.2023
Sernova Corp.
Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
First iPSC-derived commercially viable off-the-shelf islet combination product is advancing towards regulatory filing in 2024 for anticipated clinical trial authorization to treat patients wit [ … ]
Tue, 06.12.2022
Sernova Corp.
The Company is recruiting a new CEO for its next stage of growth - Dr. Toleikis, President and CEO, to transition to Chief Technology Officer upon new appointment
LONDON, Ontario -- December 6, 2022 -- Sernova Corp. (Sernova) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that, as [ … ]